Newport Academy Reviews Teen Mental Health Outcomes, Celebrates Significant Treatment Success
NASHVILLE, Tenn., May 28, 2025 /PRNewswire/ -- Newport Academy, the nation's leading mental health treatment program for adolescents ages 12–18, reviewed data from its teen mental health outcomes and found significant improvements in depression and anxiety symptoms, well-being, suicide risk, traumatic distress, and attachment to parents and caregivers. Through the Newport Healthcare Center for Research and Innovation, Newport Academy surveyed over 3,600 teens who attended its residential and outpatient programs last year to measure treatment success. The results were published in Newport's annual Science of Healing report.
"While May's Mental Health Awareness Month may be concluding, our commitment to providing data-informed, life-changing care for teens and their families continues," said Newport's Chief Executive Officer, Brian Setzer. "We are proud to celebrate our exceptional outcomes that reflect the skill and compassion of our multidisciplinary teams, as well as their dedication to helping resolve the myriad issues that trouble teens."
Newport Academy reviews data from teens and families at multiple points during treatment to inform individual treatment plans and overall programming. The outcomes report notes that teens in Newport Academy residential programs who had been experiencing anxiety and/or depression improved from "poor" to "well" over the course of treatment. Additionally, the number experiencing suicidal thoughts dropped by 50% after five weeks of treatment. Importantly, data showed that the clinical gains made during residential treatment were maintained 90 days post-discharge.
The survey also asked teens about their general functioning across various areas of their life or, more specifically, their ability to cope with everyday demands. Post-discharge, former Newport Academy clients reported higher functioning in all domains, reflecting Newport's focus on helping teens build healthy coping skills and authentic relationships.
Newport Academy's whole-person treatment approach recognizes and addresses each teen's unique mental health journey and symptoms. And while 40% of adolescents who entered Newport Academy residential care felt they needed mental health support and wanted to start treatment, even teens who were not motivated or were "treatment resistant" made positive connections with their family therapist, progressed toward their treatment goals early on, and experienced significant improvement, on average, across all mental health measures, according to the report. Through individually tailored treatment plans, ongoing family involvement, and industry-leading staff-to-client ratios, Newport achieves meaningful patient engagement that leads to long-lasting results.
Newport offers nationwide mental health treatment locations and in-network status with most major insurance providers. View the full outcomes report at newportacademy.com/outcomes.
About Newport Academy
Newport Academy is the nation's leading mental health treatment program for adolescents ages 12–18 and their families. With residential and outpatient locations across the United States, Newport Academy provides individualized treatment that includes clinical therapy, experiential modalities, and academic support. Newport's integrated approach is proven to enhance teen well-being, strengthen family relationships, and give young people the skills they need to thrive.
Newport Academy is part of the Newport Healthcare family of programs, which also includes Newport Institute, Center for Families, and PrairieCare. Newport Healthcare's full continuum of care includes nationwide residential services, Partial Hospitalization Programs (PHP), and Intensive Outpatient Programs (IOP) for mental health and substance use disorders, as well as psychiatric inpatient services in Minnesota. Newport's family-centered, integrated approach fosters sustainable healing from a foundation of compassionate care, clinical expertise, and unconditional love, with a primary mission to empower lives and restore families.
MEDIA CONTACT:5W Public RelationsNewportAcademy@5wpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/newport-academy-reviews-teen-mental-health-outcomes-celebrates-significant-treatment-success-302466498.html
SOURCE Newport Healthcare
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
New data from DR.CI:LABO™ at IMCAS Asia 2025 reinforces leadership in adjunctive clinical skincare for daily and post-IPL care for Asian skin
SINGAPORE, June 10, 2025 /PRNewswire/ -- Japan's clinic-born leading derma-cosmetics brand, unveiled new findings at IMCAS Asia 2025, reaffirming its position as the go-to skincare brand for Asian skin. The data demonstrated the efficacy of VC100 Essence Lotion EX and 377VC Radiance Serum in improving skin hydration, elasticity, and pigmentation when used daily and post-IPL[1] care. "At IMCAS Asia 2025, we're proud to present new clinical evidence that reflects the needs of today's consumers and supports their aesthetic and skincare choices. Our role is to provide safe, effective skincare solutions like VC100 Essence Lotion EX and 377VC Radiance Serum that can be used as daily skincare, enhance recovery and extend results of aesthetic treatments," said Dr. Sheila Chua, Board-Certified Dermatologist and Head of Medical & Safety Sciences, Skin Health & Beauty, Kenvue Asia Pacific. VC100 Essence Lotion EX: Now with clinically proven efficacy for regular daily and post-IPL care At IMCAS Asia 2025, presented new clinical data highlighting the benefits of twice-daily use of VC100 Essence Lotion EX over eight weeks on Asian skin. Powered by 100 trillion Micro-High Penetrating APPS Vitamin C, the formulation delivered visible improvements across key skin indicators including hydration, elasticity and gloss by 21.6%, 14.6%, 8.7% respectively, and reduction in hyperpigmentation by 5.9%.[2] The study also showed a significant boost in the synthesis of five different types of collagen, increased collagen density, and skin firmness. This builds on findings presented at the American Academy of Dermatology 2025, where twice daily use of VC100 Essence Lotion EX and Emulsion over a span of eight weeks showed a similar trend of improvement to IPL.[3],[4] When used in combination with IPL, hydration and elasticity improved by 25.4% and 15.5% respectively, compared to 20.8% and 10.9% with IPL alone, and hyperpigmentation reduction accelerated, with visible improvement by Week Two. 377VC Radiance Serum: A proven brightening adjunct for IPL-treated skin also shared clinical data on 377VC Radiance Serum at IMCAS. In a five-week, randomized controlled trial, participants who used the serum daily post-IPL showed a 31.88% reduction in Melasma Area and Severity Index and a 22.13% reduction in hyperpigmentation, compared to 8.92% and 8.52% in participants that only received IPL.[5] Skin image analysis further indicates reversing and reduced risk of potential re-darkening after IPL. The serum was well tolerated on treated skin in favorable state, supporting its use in post-IPL care and reaffirming its safety profile.[5] Findings presented at IMCAS from a survey of 844 dermatologists in China validated clinical approach and reinforces its clinical credibility: 83% agreed that 377VC Radiance Serum reduces melanin synthesis and improves skin brightness, Over 75% believed it enhances post-IPL outcomes and helps prevent post-inflammatory hyperpigmentation, and 99% acknowledged growing patient demand for adjunctive clinical skincare.[6] For a detailed overview of products and posters exhibited, refer to the Data and Product Fact Sheet. For more information, visit the website. About Since 1999, has pioneered the advancement of skincare solutions in collagen health. For over 25 years, is dedicated to providing skincare solutions that unlock the potential for beauty within every skin and democratize access to clinic level treatments for all. [1] Intense Pulsed Laser [2] Taichi Nishizawa et. al., "Ex-vivo and Clinical Study of an Amphiphilic Vitamin C Derivative to Enhance Dermal Collagen and Skin Gloss", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [3] Frequency of IPL treatment administered: 3 times every 2 weeks, over 8 weeks (IPL output: 10-13J, about 100 shots). [4] Masahiko Ando et. al., Clinical efficacy assessment of skin care formulations containing trisodium ascorbyl6-palmitate 2-phosphate (APPS) for pre-aging skin, Poster number 61671, American Academy of Dermatology Annual Meeting, 7-11 March 2025, Orlando, Florida [5] Yueying Fu et. al., "Clinical Safety and Efficacy of a Novel Topical Phenylethyl Resorcinol Formulation for Intense Pulsed Light Adjunctive Usage for Solar Lentigo and Melasma skin", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [6] Joleen Goh et. al., "Knowledge, Attitude, and Practice Towards the Adjunctive Perioperative Use of Phenylethyl Resorcinol with Aesthetic Treatments", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand View original content to download multimedia: SOURCE Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
APhA withholds endorsement of ACIP Adult Immunization Schedule
WASHINGTON, June 9, 2025 /PRNewswire/ -- APhA is the only pharmacy representative among several professional organizations that reviews and evaluates the ACIP Adult Immunization Schedule annually. Recently, there have been several updates to the COVID-19 vaccine recommendations made by the Department of Health & Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). These changes include removing the recommendation for people who are pregnant to receive the COVID-19 vaccine. Studies have shown that people who are pregnant or were recently pregnant are: More likely to get very sick from COVID-19 compared to those who are not. More likely to need hospitalization, intensive care, or the use of a ventilator or special equipment to breathe if they do get sick from COVID-19. At increased risk of complications that can affect pregnancy and the baby, including preterm birth or stillbirth. COVID-19 vaccination during pregnancy has been proven safe and effective. Additionally, this vaccine is not associated with any fertility issues in either women or men. APhA's stance is that pregnancy is a high-risk condition; therefore, people who are pregnant should be recommended to receive the COVID-19 vaccine. The May 2025 updates to the COVID-19 vaccine recommendations do not appear to be based on the scientific evidence provided over the past few years. Considering this recent change, APhA has decided to withhold endorsing the current ACIP Adult Immunization Schedule issued on May 28, 2025. This decision was proposed by a group of APhA members who are immunization subject matter experts and approved by the APhA Board of Trustees. APhA requests, and is hopeful, that future updates of the Adult Immunization Schedule be based on scientific evidence and would reconsider its endorsement upon the schedule being discussed and recommended by ACIP. View original content to download multimedia: SOURCE American Pharmacists Association
Yahoo
3 hours ago
- Yahoo
Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill
WASHINGTON, June 9, 2025 /PRNewswire/ -- The Nigerian Physician Advocacy Group (NPAG), will host a two-day Advocacy & Lobby Day on June 10–11, 2025, on Capitol Hill to highlight the vital role Nigerian American physicians play in filling healthcare shortages and call on Congress to remove systemic barriers to their continued service by reforming the J-1 visa program and passing the Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201), also known as the "Doctors in Our Borders" bill. The NPAG delegation will be led by Dr. Susan Edionwe, Nigerian American physicians, health advocates, and community leaders. This initiative comes amid targets on international students at U.S. universities and growing concerns over the increasing number of J-1 visa denials, which prevent qualified international medical graduates (IMGs)—especially Nigerian-trained physicians—from contributing their expertise to underserved and rural communities across the United States. Nigerian American physicians have played an important role in filling healthcare shortages in the United States and the advancement of our country's healthcare system is dependent on the removal of systemic barriers to their continued service. "Doctors from Nigeria and across Africa have long served in America's most vulnerable communities—from inner cities to remote rural counties," said Dr. Susan Edionwe. "Fixing the J-1 process and passing H.R. 1201 is essential to ensuring our communities have access to the care they desperately need." "NPAG encourages policymakers, allies, and the media to recognize the indispensable contribution of Nigerian and African-trained doctors to the American healthcare system—and to take legislative action to protect and expand their role in advancing national health equity," said Dr. Susan Edionwe. About Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201): H.R. 1201 a bipartisan bill, would reauthorize and expand the Conrad 30 waiver program, which allows J-1 physicians to remain in the U.S. after residency by serving in Health Professional Shortage Areas (HPSAs). The legislation provides states with greater flexibility, increases waiver caps, and reduces processing delays—ensuring medically underserved communities continue receiving essential care. About NPAG: The Nigerian Physician Advocacy Group is a national coalition of Nigerian American doctors and advocates committed to advancing health equity, shaping inclusive immigration policy, and addressing physician workforce challenges in the United States. View original content to download multimedia: SOURCE Nigerian Physician Advocacy Group (NPAG)
